Kisha Piggott, MD
Retina Specialist · Saint Louis, MONPI 1316236482
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,000 of the $5,656 with a category attached, or 70.7%. Novartis accounts for 86.1% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2019 at $4,869 and has fallen 92.3% since, to $375 in 2025.
Across 14 payments — averaging $404.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$5K
- Regeneron$215
- Alcon$149
- Apellis Pharmaceuticals, Inc.$132
- Astellas Pharma US Inc$124
- Regeneron Healthcare Solutions, Inc.$122
- plus $45 from 2 others
What the payments were for
- Consulting fees$4,00071%
- Travel & lodging$62211%
- Food & beverage$1,03518%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 6 | $4,869 |
| Regeneron | 2 | $215 |
| Alcon | 1 | $149 |
| Apellis Pharmaceuticals, Inc. | 1 | $132 |
| Astellas Pharma US Inc | 1 | $124 |
| Regeneron Healthcare Solutions, Inc. | 1 | $122 |
| Sun Pharmaceutical Industries Inc. | 1 | $23 |
| Alimera Sciences, Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,656 in reported general payments places this provider in the 75th percentile of 45 retina specialist providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 87 | $2,683 |
| Ketorolac Tromethamine | 44 | $615 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 33 | $340 |
| Latanoprost | 33 | $216 |
| Tobramycin | 54 | $195 |
| Brimonidine Tartrate | 42 | $192 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 11 | $109 |
| ErythromycinErythromycin Base | 11 | $75 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Saint Louis
- Aaron LeeSaint Louis$214K
- Mark GrandSaint Louis$3K
- Vichar TrivediSaint Louis$2K
- Niloofar PiriSaint Louis$1K
- Parth ShahSaint Louis$958
- Bliss O'BryhimSaint Louis$863
- Georgia WilkeSaint Louis$730
- Daniel JosephSaint Louis$395
- Rithwick RajagopalSaint Louis$244
- Cecilia LeeSaint Louis$204
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.